Riskpilot← Back to searchSign inGet full accessZPEARPOINT AS
ASActiveOrg 991650385Hagaløkkveien 26, 1383 AskerManufacture of pharmaceutical preparations · NACE 2120Est. 20070 employeeswww.meda.no
Revenue 2024
NOK 0
EBITDA margin
—
-108% vs 2023
Equity ratio
18.4%
Financial strength
Net profit 2024
NOK 85K
-27% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -52K | -108% |
| Net profit | NOK 85K | -27% |
| Total assets | NOK 774K | -3% |
| Equity | NOK 142K | -27% |
| Employees | 0 | — |
Legal name
ZPEARPOINT AS
Org number
991650385
Legal form
Aksjeselskap
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
10. september 2007
Share capital
NOK 117 223
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets medlemmer hver for seg.
Company purpose
Utvikling, produksjon, markedsføring og salg av legemiddel og lignende produkter innen tannlegebransjen samt investering i annen virksomhet.
Address
Hagaløkkveien 26, 1383 Asker
Website
www.meda.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −22 | −22 | −12 | −25 | −52 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −22 | −22 | −12 | −25 | −52 |
| Net financials | −60 | −3 | −1 | 1 | −1 |
| Profit before tax | −82 | −25 | −13 | −24 | −53 |
| Tax | −154 | −141 | −139 | −141 | −139 |
| Net profit | 72 | 116 | 126 | 117 | 85 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 818 | 1 436 | 809 | 796 | 774 |
| Equity | 818 | 191 | 178 | 196 | 142 |
| Long-term debt | 0 | 0 | 0 | 0 | 0 |
| Short-term debt | 0 | 1 244 | 631 | 600 | 631 |
| Total debt | 0 | 1 244 | 631 | 600 | 631 |
EBITDA margin
-5200000.0%
This company
15.8%
Market median
-32911492% vs market
20202024
Equity ratio
18.4%
This company
38.2%
Market median
-52% vs market
20202024
Return on equity
60.0%
This company
18.4%
Market median
+226% vs market
20202024
Net profit margin
8546700.0%
This company
8.1%
Market median
+105514715% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
4.43×
This company
0.62×
Market median
-615% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
LH Chief Executive Officer | Chief Executive Officer | 2026 |
JU Chief Executive Officer | Chief Executive Officer | 2020 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Board of Directors | 2023 | |
| Chairman | 2023 | |
| Former (2) | ||
| Board of Directors | 2021 – 2023 | |
| Chairman | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Antula Healthcare Ab | Company | 100% | 100% | 2023 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of ZPEARPOINT AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Lars Henrik Andreas Rejnus | Chief Executive Officer | 0 companies |
| Jan Ulrik Stevnsborg | Chief Executive Officer | 0 companies |
| Bente Brumoen | Board of Directors | 0 companies |
| Kurt Glud | Board of Directors | 0 companies |
| Luis Rodolfo Birbuet | Chairman | 0 companies |
| Arun Narayan | Chairman | 0 companies |